Updated
Updated · The Washington Post · Nov 17
Sellas' GPS Leukemia Vaccine Cuts Death Risk 41% in 126-Patient Phase 3 Trial
Updated
Updated · The Washington Post · Nov 17

Sellas' GPS Leukemia Vaccine Cuts Death Risk 41% in 126-Patient Phase 3 Trial

3 articles · Updated · The Washington Post · Nov 17

Summary

  • Sellas and Memorial Sloan Kettering said galinpepimut-S succeeded in a Phase 3 trial for acute myeloid leukemia, with treated patients showing a 41% lower risk of death than those on other therapies.
  • Median survival reached 24 months with GPS versus 14.7 months for comparison treatment in 126 patients who had entered a second or later remission and were ineligible for bone-marrow transplant.
  • Sellas said the peptide-based vaccine was generally well tolerated, with side effects mostly limited to injection-site reactions; full data, including leukemia-free and relapse-free survival, will be presented later.
  • The off-the-shelf design distinguishes GPS from personalized cancer vaccines such as this year's successful melanoma shot intismeran, suggesting multiple viable paths for cancer immunization.
  • Sellas plans to prepare an FDA submission in the first half of 2027 for a patient group that experts say has had few treatment options.

Insights

How will the success of the GPS vaccine reshape the future of scalable immunotherapies ahead of its 2027 FDA review?
Could this off-the-shelf peptide vaccine permanently prevent leukemia relapses for patients who have exhausted all other treatment options?
What hidden challenges might emerge when targeting the WT1 protein to stop acute myeloid leukemia from returning?

SELLAS’ Galinpepimut-S Delivers 41% Lower Death Risk in AML Phase 3 Trial, Paving Way for FDA Approval and Multi-Cancer Expansion

Overview

On November 17, 2026, SELLAS Life Sciences announced positive Phase 3 results for galinpepimut-S (GPS) in acute myeloid leukemia, showing a 41% reduction in risk of death and extending median survival to 24 months versus 14.7 months for standard treatment. This breakthrough led to a dramatic 170% surge in SELLAS’s stock price. The results surprised industry skeptics and prompted SELLAS to plan for FDA engagement and a regulatory submission in early 2027. GPS’s design uses AI-engineered peptide mutations to overcome immune tolerance, targets cancer-specific WT1 protein, and offers off-the-shelf, cost-effective therapy with fewer side effects than traditional treatments.

...